Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Retained Earnings (2018 - 2025)

X4 Pharmaceuticals' Retained Earnings history spans 8 years, with the latest figure at -$594.6 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 487239.34% year-over-year to -$594.6 million; the TTM value through Dec 2025 reached -$594.6 million, down 487239.34%, while the annual FY2025 figure was -$594.6 million, 487239.34% down from the prior year.
  • Retained Earnings reached -$594.6 million in Q4 2025 per XFOR's latest filing, down from -$570.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$119000.0 in Q2 2021 to a low of -$594.6 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$246.6 million, with a median of -$293.9 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 99.97% in 2023, then plummeted 487239.34% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$282.9 million in 2021, then plummeted by 33.18% to -$376.7 million in 2022, then skyrocketed by 99.97% to -$119000.0 in 2023, then decreased by 2.52% to -$122000.0 in 2024, then tumbled by 487239.34% to -$594.6 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Retained Earnings are -$594.6 million (Q4 2025), -$570.6 million (Q3 2025), and -$540.8 million (Q2 2025).